Pharmacologie

Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration.

Published on - Journal of Chemical Biology

Authors: Sylvain Thierry, Mohamed Salah Benleulmi, Ludivine Sinzelle, Eloise Thierry, Christina Calmels, Stephane Chaignepain, Pierre Waffo-Teguo, Jean-Michel Merillon, Brian Budke, Jean-Max Pasquet, Simon Litvak, Angela Ciuffi, Patrick Sung, Philip Connell, Ilona Hauber, Joachim Hauber, Marie-Line Andreola, Olivier Delelis, Vincent Parissi

The cellular DNA repair hRAD51 protein has been shown to restrict HIV-1 integration both in vitro and in vivo. To investigate its regulatory functions, we performed a pharmacological analysis of the retroviral integration modulation by hRAD51. We found that, in vitro, chemical activation of hRAD51 stimulates its integration inhibitory properties, whereas inhibition of hRAD51 decreases the integration restriction, indicating that the modulation of HIV-1 integration depends on the hRAD51 recombinase activity. Cellular analyses demonstrated that cells exhibiting high hRAD51 levels prior to de novo infection are more resistant to integration. On the other hand, when hRAD51 was activated during integration, cells were more permissive. Altogether, these data establish the functional link between hRAD51 activity and HIV-1 integration. Our results highlight the multiple and opposite effects of the recombinase during integration and provide new insights into the cellular regulation of HIV-1 replication.